Glucarpidase should soon be approved throughout Europe to treat methotrexate toxicity. The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently recommended the ...

Please provide your email address to receive an email when new articles are posted on . Patients who received glucarpidase for acute kidney injury from methotrexate treatment had improved kidney ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

Glucarpidase may improve kidney function and other sequelae in patients with methotrexate-induced acute kidney injury. High-dose methotrexate frequently causes acute kidney injury (MTX-AKI), ...

Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome. BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic ...

A new model can predict which patients are more likely to experience side effects from long-term methotrexate (MTX) use, research suggests. Patients with a lower risk profile may benefit from less ...

Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With N-Phosphonacetyl-l-aspartate, Folinic Acid, and Interferon Alfa PURPOSE: Hemodialysis, hemoperfusion, ...

Please provide your email address to receive an email when new articles are posted on . Low-dose methotrexate did not relieve pain or reduce synovitis in inflammatory knee OA. The findings do not ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators ...

Up to three quarters of patients receiving cancer chemotherapy suffer from "chemo brain" - a long-term side effect that makes it harder to remember things, maintain attention, and learn new ...